ATE258440T1 - Verwendung von neutralen gallium chelaten mit 3- hydroxy-4-pyrone verbindungen zur behandlung von krankheiten die verbessert werden können durch die hemmung der hyperproliferation von keratinocyten - Google Patents

Verwendung von neutralen gallium chelaten mit 3- hydroxy-4-pyrone verbindungen zur behandlung von krankheiten die verbessert werden können durch die hemmung der hyperproliferation von keratinocyten

Info

Publication number
ATE258440T1
ATE258440T1 AT97938025T AT97938025T ATE258440T1 AT E258440 T1 ATE258440 T1 AT E258440T1 AT 97938025 T AT97938025 T AT 97938025T AT 97938025 T AT97938025 T AT 97938025T AT E258440 T1 ATE258440 T1 AT E258440T1
Authority
AT
Austria
Prior art keywords
keratinocytes
diseases
hydroxy
treatment
improved
Prior art date
Application number
AT97938025T
Other languages
English (en)
Inventor
Lawrence Richard Bernstein
Original Assignee
Lawrence Richard Bernstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence Richard Bernstein filed Critical Lawrence Richard Bernstein
Application granted granted Critical
Publication of ATE258440T1 publication Critical patent/ATE258440T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
AT97938025T 1996-07-30 1997-07-30 Verwendung von neutralen gallium chelaten mit 3- hydroxy-4-pyrone verbindungen zur behandlung von krankheiten die verbessert werden können durch die hemmung der hyperproliferation von keratinocyten ATE258440T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/688,565 US5747482A (en) 1996-07-30 1996-07-30 Methods and compositions to inhibit keratinocyte proliferation
PCT/US1997/012951 WO1998004264A1 (en) 1996-07-30 1997-07-30 Methods and compositions to inhibit keratinocyte proliferation

Publications (1)

Publication Number Publication Date
ATE258440T1 true ATE258440T1 (de) 2004-02-15

Family

ID=24764914

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938025T ATE258440T1 (de) 1996-07-30 1997-07-30 Verwendung von neutralen gallium chelaten mit 3- hydroxy-4-pyrone verbindungen zur behandlung von krankheiten die verbessert werden können durch die hemmung der hyperproliferation von keratinocyten

Country Status (8)

Country Link
US (1) US5747482A (de)
EP (1) EP0959889B1 (de)
JP (1) JP2000516219A (de)
AT (1) ATE258440T1 (de)
AU (2) AU3726797A (de)
DE (1) DE69727399T2 (de)
ES (1) ES2214635T3 (de)
WO (2) WO1998004263A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203822B1 (en) * 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
WO2001024799A1 (en) * 1999-10-04 2001-04-12 Bernstein Lawrence R Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses
US20020160055A1 (en) * 2000-09-18 2002-10-31 Jack Stapleton Methods for treating human immunodeficiency virus infections with gallium compositions
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
JP2003267966A (ja) * 2002-03-13 2003-09-25 Pola Chem Ind Inc フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤
US7081247B2 (en) * 2002-05-20 2006-07-25 Nidaria Technology Ltd. Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting
AU2003279067A1 (en) * 2002-09-23 2004-04-08 Genta Inc. Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them
EP1993567A4 (de) * 2005-10-27 2011-01-26 Lawrence Richard Bernstein Oral verabreichbare gallium-zusammensetzungen und anwendungsverfahren
KR101218854B1 (ko) * 2005-11-01 2013-01-09 사이더로믹스, 엘엘씨 갈륨 화합물을 이용한 구강 및 표면 미생물의 성장 제어
JP2009514898A (ja) * 2005-11-07 2009-04-09 タイタン ファーマシューティカルズ インコーポレイテッド ガリウムを使用する、肝臓の有害状態の処置および予防
US20070231406A1 (en) * 2006-01-30 2007-10-04 Bucalo Louis R Use of gallium to treat biofilm-associated infections
WO2008058210A2 (en) 2006-11-09 2008-05-15 Bernstein Lawrence R Local administration of gallium compositions to treat pain
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
WO2008091829A1 (en) * 2007-01-23 2008-07-31 Lawrence Bernstein Ophthalmic gallium compositions and methods of their use
WO2009009171A2 (en) * 2007-04-02 2009-01-15 Sideromics, Llc Methods for preventing or treating infectious diseases using gallium compounds
ES2336995B1 (es) * 2008-10-13 2011-02-09 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
DK3229840T5 (da) * 2014-12-12 2020-11-16 Dermavant Sciences GmbH 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne
KR102704001B1 (ko) * 2023-09-15 2024-09-06 주식회사 함소아제약 개망초 추출물을 포함하는 가려움증 개선용 화장료 조성물 제조방법 및 이에 따라 제조된 화장료 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2500303A1 (fr) * 1981-02-20 1982-08-27 Meram Lab Le chlorure de gallium, nouveau medicament anti-cancereux
EP0109564B1 (de) * 1982-10-22 1988-04-27 Sloan-Kettering Institute For Cancer Research Verwendung von Gallium-Salzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Störungen der Calcium-Homöostasis
US4704277A (en) * 1985-04-30 1987-11-03 Sloan-Kettering Institute For Cancer Research Methods of treating bone disorders
US5258376A (en) * 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
KR100196773B1 (ko) * 1990-01-12 1999-06-15 워얼렐 에스. 브로우;도날드 에스. 브로아즈 상처치유 및 조직회복을_향상시키기 위한 조성물
WO1991017751A1 (en) * 1990-05-24 1991-11-28 Fujisawa, Inc. Orally administrable gallium compositions and methods of treatment therewith
US5175006A (en) * 1990-09-21 1992-12-29 The Ohio State University Method of treating arthritis using gallium compounds
WO1993009776A1 (en) * 1991-11-12 1993-05-27 Lawrence Richard Bernstein Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones

Also Published As

Publication number Publication date
US5747482A (en) 1998-05-05
JP2000516219A (ja) 2000-12-05
AU3726797A (en) 1998-02-20
AU4044697A (en) 1998-02-20
EP0959889A1 (de) 1999-12-01
EP0959889A4 (de) 2000-08-16
ES2214635T3 (es) 2004-09-16
DE69727399D1 (de) 2004-03-04
DE69727399T2 (de) 2004-12-09
AU740198B2 (en) 2001-11-01
EP0959889B1 (de) 2004-01-28
WO1998004264A1 (en) 1998-02-05
WO1998004263A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
DE69727399D1 (de) Verwendung von neutralen Gallium Chelaten mit 3-Hydroxy-4-Pyrone Verbindungen zur Behandlung von Krankheiten die verbessert werden Können durch die Hemmung der Hyperproliferation von Keratinocyten
ATE192652T1 (de) Zusammensetzung zur behandlung von preeclampsia und frühgeburt, die ein progestatives mittel und ein stickoxyd-synthäse substrat und/oder donor enthält
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE60115000D1 (de) Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall.
ATE318133T1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
DE69512374D1 (de) Zusammensetzungen, die troxerutin als komplex mit phosphatidylcholin enthalten, zur topischen behandlung von erektionsimpotenz
ATE95060T1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
DE69720811D1 (de) L-Ribavirin und dessen Verwendung
MY101353A (en) Arylcarboxylic acid derivatives, the preparation and use thereof.
ATE367816T1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69731477D1 (de) Mittel zur akne behandlung
DE69530403D1 (de) Analogen des keratinozytenwachstumfaktors
ATE236643T1 (de) Verwendung von calendula-glykosiden zur behandlung der psoriasis
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE272404T1 (de) Verwendung von taurolidine zur herstellung eines arzneimittels zur behandlung von leukämien
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69904203D1 (de) Thiomolybdat verbunden mit mindestens einem kohlenhydrat, und seine verwendung zur vorbeugung und behandlung von erkrankungen, die durch eine anormale vaskularisierung gekennzeichnet sind, wie z.b. krebs, "feuchte" makuladegeneration, rheumatoide arthritis
DE60009919D1 (de) Antimikrobieller bodensatz
DK227090D0 (da) Organisk guldkompleks til topisk anvendelse
DE69229780D1 (de) Zusammensetzung und methode zur behandlung von störungen in form von depigmentierung
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE75396T1 (de) Verwendung von kojic-saeure oder ihres betacyclodextrin-einschlusskomplexes zur praevention von elastosis.
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties